Celecoxib/tramadol

Drug Profile

Celecoxib/tramadol

Alternative Names: E-58425; MR308; Tramadol/Celecoxib

Latest Information Update: 11 May 2017

Price : $50

At a glance

  • Originator ESTEVE
  • Developer ESTEVE; Mundipharma GmbH
  • Class Analgesics; Anti-inflammatories; Cyclohexanols; Dimethylamines; Non-opioid analgesics; Nonsteroidal anti-inflammatories; Opioid analgesics; Phenyl ethers; Pyrazoles; Small molecules; Sulfonamides
  • Mechanism of Action Adrenergic uptake inhibitors; Cyclo-oxygenase 2 inhibitors; Opioid mu receptor agonists; Serotonin uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Acute pain
  • Phase II Dental pain; Pain

Most Recent Events

  • 11 May 2017 Chemical structure information added
  • 05 Apr 2017 Phase-III clinical trials in Acute pain in Poland (PO) (NCT03062644)
  • 20 Feb 2017 Phase-III clinical trials in Acute pain in Latvia (PO) (EudraCT2016-000593-38)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top